Change search
ReferencesLink to record
Permanent link

Direct link
Impact of ABCB1 single nucleotide polymorphisms 1236C greater than T and 2677G greater than T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype
Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Health Sciences.ORCID iD: 0000-0003-4450-0333
Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Health Sciences.
Karolinska Institute, Sweden.
Karolinska Institute, Sweden.
Show others and affiliations
2014 (English)In: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 167, no 5, 671-680 p.Article in journal (Refereed) Published
Abstract [en]

Drug resistance is a clinically relevant problem in the treatment of acute myeloid leukaemia (AML). We have previously reported a relationship between single nucleotide polymorphisms (SNPs) of ABCB1, encoding the multi-drug transporter P-glycoprotein, and overall survival (OS) in normal karyotype (NK)-AML. Here we extended this material, enabling subgroup analysis based on FLT3 and NPM1 status, to further elucidate the influence of ABCB1 SNPs. De novo NK-AML patients (n = 201) were analysed for 1199Ggreater thanA, 1236Cgreater thanT, 2677Ggreater thanT/A and 3435Cgreater thanT, and correlations to outcome were investigated. FLT3 wild-type 1236C/C patients have significantly shorter OS compared to patients carrying the variant allele; medians 20 vs. 49 months, respectively, P = 0.017. There was also an inferior outcome in FLT3 wild-type 2677G/G patients compared to patients carrying the variant allele, median OS 20 vs. 35 months, respectively, P = 0.039. This was confirmed in Cox regression analysis. Our results indicate that ABCB1 1236Cgreater thanT and 2677Ggreater thanT may be used as prognostic markers to distinguish relatively high risk patients in the intermediate risk FLT3 wild-type group, which may contribute to future individualizing of treatment strategies.

Place, publisher, year, edition, pages
Wiley , 2014. Vol. 167, no 5, 671-680 p.
Keyword [en]
acute myeloid leukaemia; ABCB1; single nucleotide polymorphism; anthracyclines; FLT3
National Category
Clinical Medicine
URN: urn:nbn:se:liu:diva-112996DOI: 10.1111/bjh.13097ISI: 000345222100009PubMedID: 25155901OAI: diva2:779143

Funding Agencies|Swedish Cancer Society; County Council of Ostergotland; AFA Insurance; Stockholm Cancer Society; Karolinska Institutet; Swedish Research Council

Available from: 2015-01-12 Created: 2015-01-08 Last updated: 2015-10-09

Open Access in DiVA

fulltext(1481 kB)69 downloads
File information
File name FULLTEXT01.pdfFile size 1481 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Jakobsen Falk, IngridFyrberg, AnnaGreen, HenrikLotfi, Kourosh
By organisation
Division of Drug ResearchFaculty of Health SciencesDepartment of Clinical Pharmacology
In the same journal
British Journal of Haematology
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 69 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 91 hits
ReferencesLink to record
Permanent link

Direct link